In the present study, patients with shorter PAH history, initial triple combination treatment and relatively minor disease severity, characterized by lower NT-proBNP levels and smaller RAA (30), tended to respond better to selexipag. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.